Industry: Healthcare
Published Date: August-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 181
Report ID: PMRREP34569
1. Executive Summary
1.1. Global Neuroendocrine Carcinoma Treatment Market Snapshot, 2024 and 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global GDP Growth Outlook
2.3.2. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Product Adoption Analysis
3.2. Epidemiology - Carcinoma
3.3. Regulatory Landscape
3.4. Value Chain Analysis
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis
4. Global Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
4.1. Global Neuroendocrine Carcinoma Treatment Market Outlook: Indication
4.1.1. Introduction / Key Findings
4.1.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2018 - 2022
4.1.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
4.1.3.1. Gastric Neuroendocrine Tumors
4.1.3.2. Lung Neuroendocrine Tumors
4.1.3.3. Pancreatic Neuroendocrine Tumors
4.1.3.4. Appendicular Neuroendocrine Tumors
4.2. Market Attractiveness Analysis: Indication
4.3. Global Neuroendocrine Carcinoma Treatment Market Outlook: Treatment Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Treatment Type, 2018 - 2022
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031
4.3.3.1. Targeted Therapy
4.3.3.1.1. Tyrosine Kinase Inhibitors
4.3.3.1.2. mTOR Inhibitor
4.3.3.2. Chemotherapy
4.3.3.2.1. Antimetabolites
4.3.3.2.2. Alkylating Agents
4.3.3.2.3. Natural Products
4.3.3.3. Surgery
4.3.3.3.1. Curative Surgery
4.3.3.3.2. Palliative Surgery
4.3.3.3.3. Others
4.4. Market Attractiveness Analysis: Treatment Type
4.5. Global Neuroendocrine Carcinoma Treatment Market Outlook: End-user
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, By End-user, 2018 - 2022
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031
4.5.3.1. Hospitals
4.5.3.2. Clinics
4.5.3.3. Oncology Treatment Centers
4.5.3.4. Ambulatory Surgical Centers
4.5.3.5. Research Institutes
4.6. Market Attractiveness Analysis: End-user
5. Global Neuroendocrine Carcinoma Treatment Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2018 - 2022
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2023 - 2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Indication
6.3.3. By Treatment Type
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
6.4.1. U.S.
6.4.2. Canada
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
6.5.1. Gastric Neuroendocrine Tumors
6.5.2. Lung Neuroendocrine Tumors
6.5.3. Pancreatic Neuroendocrine Tumors
6.5.4. Appendicular Neuroendocrine Tumors
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031
6.6.1. Targeted Therapy
6.6.1.1. Tyrosine Kinase Inhibitors
6.6.1.2. mTOR Inhibitor
6.6.2. Chemotherapy
6.6.2.1. Antimetabolites
6.6.2.2. Alkylating Agents
6.6.2.3. Natural Products
6.6.3. Surgery
6.6.3.1. Curative Surgery
6.6.3.2. Palliative Surgery
6.6.4. Others
6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031
6.7.1. Hospitals
6.7.2. Clinics
6.7.3. Oncology Treatment Centers
6.7.4. Ambulatory Surgical Centers
6.7.5. Research Institutes
6.8. Market Attractiveness Analysis
7. Europe Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Indication
7.3.3. By Treatment Type
7.3.4. By End-user
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
7.4.1. Germany
7.4.2. France
7.4.3. U.K.
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Türkiye
7.4.8. Rest of Europe
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
7.5.1. Gastric Neuroendocrine Tumors
7.5.2. Lung Neuroendocrine Tumors
7.5.3. Pancreatic Neuroendocrine Tumors
7.5.4. Appendicular Neuroendocrine Tumors
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031
7.6.1. Targeted Therapy
7.6.1.1. Tyrosine Kinase Inhibitors
7.6.1.2. mTOR Inhibitor
7.6.2. Chemotherapy
7.6.2.1. Antimetabolites
7.6.2.2. Alkylating Agents
7.6.2.3. Natural Products
7.6.3. Surgery
7.6.3.1. Curative Surgery
7.6.3.2. Palliative Surgery
7.6.4. Others
7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031
7.7.1. Hospitals
7.7.2. Clinics
7.7.3. Oncology Treatment Centers
7.7.4. Ambulatory Surgical Centers
7.7.5. Research Institutes
7.8. Market Attractiveness Analysis
8. East Asia Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Indication
8.3.3. By Treatment Type
8.3.4. By End-user
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
8.4.1. China
8.4.2. Japan
8.4.3. South Korea
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
8.5.1. Gastric Neuroendocrine Tumors
8.5.2. Lung Neuroendocrine Tumors
8.5.3. Pancreatic Neuroendocrine Tumors
8.5.4. Appendicular Neuroendocrine Tumors
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031
8.6.1. Targeted Therapy
8.6.1.1. Tyrosine Kinase Inhibitors
8.6.1.2. mTOR Inhibitor
8.6.2. Chemotherapy
8.6.2.1. Antimetabolites
8.6.2.2. Alkylating Agents
8.6.2.3. Natural Products
8.6.3. Surgery
8.6.3.1. Curative Surgery
8.6.3.2. Palliative Surgery
8.6.4. Others
8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031
8.7.1. Hospitals
8.7.2. Clinics
8.7.3. Oncology Treatment Centers
8.7.4. Ambulatory Surgical Centers
8.7.5. Research Institutes
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Indication
9.3.3. By Treatment Type
9.3.4. By End-user
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
9.4.1. India
9.4.2. Southeast Asia
9.4.3. ANZ
9.4.4. Rest of South Asia & Oceania
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
9.5.1. Gastric Neuroendocrine Tumors
9.5.2. Lung Neuroendocrine Tumors
9.5.3. Pancreatic Neuroendocrine Tumors
9.5.4. Appendicular Neuroendocrine Tumors
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031
9.6.1. Targeted Therapy
9.6.1.1. Tyrosine Kinase Inhibitors
9.6.1.2. mTOR Inhibitor
9.6.2. Chemotherapy
9.6.2.1. Antimetabolites
9.6.2.2. Alkylating Agents
9.6.2.3. Natural Products
9.6.3. Surgery
9.6.3.1. Curative Surgery
9.6.3.2. Palliative Surgery
9.6.4. Others
9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031
9.7.1. Hospitals
9.7.2. Clinics
9.7.3. Oncology Treatment Centers
9.7.4. Ambulatory Surgical Centers
9.7.5. Research Institutes
9.8. Market Attractiveness Analysis
10. Latin America Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Indication
10.3.3. By Treatment Type
10.3.4. By End-user
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Rest of Latin America
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
10.5.1. Gastric Neuroendocrine Tumors
10.5.2. Lung Neuroendocrine Tumors
10.5.3. Pancreatic Neuroendocrine Tumors
10.5.4. Appendicular Neuroendocrine Tumors
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031
10.6.1. Targeted Therapy
10.6.1.1. Tyrosine Kinase Inhibitors
10.6.1.2. mTOR Inhibitor
10.6.2. Chemotherapy
10.6.2.1. Antimetabolites
10.6.2.2. Alkylating Agents
10.6.2.3. Natural Products
10.6.3. Surgery
10.6.3.1. Curative Surgery
10.6.3.2. Palliative Surgery
10.6.4. Others
10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031
10.7.1. Hospitals
10.7.2. Clinics
10.7.3. Oncology Treatment Centers
10.7.4. Ambulatory Surgical Centers
10.7.5. Research Institutes
10.8. Market Attractiveness Analysis
11. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
11.1. Key Highlights
11.2. Pricing Analysis
11.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
11.3.1. By Country
11.3.2. By Indication
11.3.3. By Treatment Type
11.3.4. By End-user
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
11.4.1. GCC Countries
11.4.2. Egypt
11.4.3. South Africa
11.4.4. Northern Africa
11.4.5. Rest of Middle East & Africa
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
11.5.1. Gastric Neuroendocrine Tumors
11.5.2. Lung Neuroendocrine Tumors
11.5.3. Pancreatic Neuroendocrine Tumors
11.5.4. Appendicular Neuroendocrine Tumors
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031
11.6.1. Targeted Therapy
11.6.1.1. Tyrosine Kinase Inhibitors
11.6.1.2. mTOR Inhibitor
11.6.2. Chemotherapy
11.6.2.1. Antimetabolites
11.6.2.2. Alkylating Agents
11.6.2.3. Natural Products
11.6.3. Surgery
11.6.3.1. Curative Surgery
11.6.3.2. Palliative Surgery
11.6.4. Others
11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031
11.7.1. Hospitals
11.7.2. Clinics
11.7.3. Oncology Treatment Centers
11.7.4. Ambulatory Surgical Centers
11.7.5. Research Institutes
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Pfizer Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Novartis AG
12.3.2.1. Overview
12.3.2.2. Segments and Products
12.3.2.3. Key Financials
12.3.2.4. Market Developments
12.3.2.5. Market Strategy
12.3.3. Chiasma Inc.
12.3.3.1. Overview
12.3.3.2. Segments and Products
12.3.3.3. Key Financials
12.3.3.4. Market Developments
12.3.3.5. Market Strategy
12.3.4. Hutchison China MediTech Ltd
12.3.4.1. Overview
12.3.4.2. Segments and Products
12.3.4.3. Key Financials
12.3.4.4. Market Developments
12.3.4.5. Market Strategy
12.3.5. Abbvie Inc.
12.3.5.1. Overview
12.3.5.2. Segments and Products
12.3.5.3. Key Financials
12.3.5.4. Market Developments
12.3.5.5. Market Strategy
12.3.6. valeant Pharmaceuticals International Inc.
12.3.6.1. Overview
12.3.6.2. Segments and Products
12.3.6.3. Key Financials
12.3.6.4. Market Developments
12.3.6.5. Market Strategy
12.3.7. Jubilant Life Sciences Ltd.
12.3.7.1. Overview
12.3.7.2. Segments and Products
12.3.7.3. Key Financials
12.3.7.4. Market Developments
12.3.7.5. Market Strategy
12.3.8. Teva Pharamaceuticals Industries Ltd
12.3.8.1. Overview
12.3.8.2. Segments and Products
12.3.8.3. Key Financials
12.3.8.4. Market Developments
12.3.8.5. Market Strategy
12.3.9. F. Hoffman-La Roche Ltd
12.3.9.1. Overview
12.3.9.2. Segments and Products
12.3.9.3. Key Financials
12.3.9.4. Market Developments
12.3.9.5. Market Strategy
12.3.10. Advanced Accelerator Applications
12.3.10.1. Overview
12.3.10.2. Segments and Products
12.3.10.3. Key Financials
12.3.10.4. Market Developments
12.3.10.5. Market Strategy
12.3.11. Mateon Therapeutics, Inc.
12.3.11.1. Overview
12.3.11.2. Segments and Products
12.3.11.3. Key Financials
12.3.11.4. Market Developments
12.3.11.5. Market Strategy
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
